CMX001-210

CMX001-210

A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant (HCT) Recipients With Adenovirus Viremia


Treatment


Inclusion criteria


Exclusion criteria


Participating sites


Link